Brady Revenue Jumps 16% in Fiscal Q4

Brady (NYSE:BRC) reported record Q4 fiscal 2025 adjusted EPS of $1.26 on revenue of $397.3 million, a 15.7% increase. However, this revenue growth was primarily acquisition-driven, with organic sales up a modest 2.4%. Margins contracted and operating cash flow declined significantly, largely due to organic sales shrinkage and restructuring costs in the Europe & Australia segment, despite some momentum in Americas & Asia. Management provided optimistic FY2026 EPS guidance, though future investor focus will be on the pace of organic growth, margin trajectory, and cash flow management.

Analysis

Brady Corporation's (BRC) fiscal Q4 2025 results present a narrative of acquisition-fueled top-line growth that masks underlying operational weaknesses. The reported 15.7% revenue increase to $397.3 million and record adjusted EPS of $1.26 are overshadowed by the fact that organic sales grew a mere 2.4%, with acquisitions contributing 11.3 percentage points to sales. Profitability is a significant concern, as margins contracted and segment profits declined across the board; the Americas & Asia segment profit fell 3.4% despite sales growth, while the Europe & Australia segment profit plunged 21.9% amid a 1.3% organic sales decline and $8.9 million in restructuring costs. Furthermore, the company's financial health shows signs of pressure, evidenced by a 30.3% year-over-year drop in cash and cash equivalents to $174.3 million. While management has issued optimistic EPS guidance for fiscal 2026, projecting up to 12.0% growth in adjusted EPS, achieving this will depend heavily on successfully integrating acquisitions and the efficacy of cost-cutting, as current organic performance and cash flow trends are weak.

Key Decisions for Investors

• Investors should look past the headline 15.7% revenue growth and focus on the stagnant 2.4% organic growth rate and declining segment profitability as more accurate indicators of the company's core operational health.
• Closely monitor the margin trajectory in the Americas & Asia and Europe & Australia segments, as the latter's 21.9% profit decline and ongoing restructuring represent a significant risk to achieving forward-looking guidance.
• The 30.3% year-over-year decline in cash and equivalents warrants caution; assess the sustainability of the $96.4 million capital return program and the company's ability to fund its record R&D investments without further impacting liquidity.